Most interestingly, correlation of MLPH expression to clinicopathological variables of patients revealed a clear correlation of higher expression with a favorable risk profile, including lower Gleason grades, lower pathological stages, smaller relative tumor mass, absence of biochemical tumor recurrence, and lower serum PSA. Here, PROS1 is linked to neoplasm.